Current issue
Archive
Videos
Articles in press
About the journal
Supplements
Editorial board
Reviewers
Abstracting and indexing
Subscription
Contact
Instructions for authors
Publication charge
Ethical standards and procedures
Editorial System
Submit your Manuscript
|
1/2019
vol. 121 abstract:
Original paper
Comparison of efficacy and safety of postoperative treatment with loteprednol etabonate and bromfenac after phacoemulsification
Magdalena Kucharczyk-Pośpiech
1
,
Piotr Jurowski
2
,
Wiktoria Kubisiak
2
,
Monika Chwiałkowska-Karam
2
,
Michał Wilczyński
1
,
Sylwia Konarska
1
,
Wojciech Omulecki
1
Online publish date: 2019/06/05
View
full text
Get citation
ENW EndNote
BIB JabRef, Mendeley
RIS Papers, Reference Manager, RefWorks, Zotero
AMA
APA
Chicago
Harvard
MLA
Vancouver
Aim
Comparison of efficacy and safety of loteprednol etabonate and bromfenac after phacoemulsification. Material and methods Multicenter prospective case series. Consecutive 58 patients (58 eyes) were randomly assigned to the one of the study groups regarding postoperative treatment. Patients in Group I used 0.09% bromfenac 2 times diurnally for 30 days, and patients in Group II used 0.5% loteprednol etabonate 4 times diurnally for 30 days. The laser flare-cell photometry, slit lamp examination, tonometry and optical coherence tomography of macula were performed preoperatively and postoperatively at 1, 7, 30 and 90 days. Results The distance best corrected visual acuity was 0. 93 in group I and 0.91 in w group II. Laser Flare Photometry, central macular thickness and intraocular pressure was not significantly different during the 3 months of treatment between the groups (p> 0.05). In both groups, there were no abnormalities in routine slit lamp examination of the anterior and posterior segment. Conclusions The results of the study suggest that topical bromfenac and topical loteprednol etabonate had similar effect on laser flare-cell photometry and foveal thickness in the postoperative period after uneventful phacoemulsification. keywords:
loteprednol etabonate, bromfenac, phacoemulsification, cataract, steroids, NSAID |
|